have patent lawyers on stand -by , page-4

Vinn,
..IMO good news for Regen Med.
This is autologous therapy which is contrasted to our Allogeneic model.

We know that there is potential for stem cells to impact on ischemic heart disease - as was indicated by the P values in a 17 patient subset trial that MSB undertook (as part of the 60 patient CHF trials).


See ASX release 9 June 2011:
...Mesoblast Chief Executive, Professor Silviu Itescu, presented results showing that the company's lead cardiovascular product Revascor™ improves blood flow in ischemic heart muscle and reduces long term vascular-related complications. On the basis of these results, Mesoblast will now proceed with Phase 2b trials of Revascor™ for the treatment of vascular conditions including chronic refractory angina and acute myocardial infarction (heart attacks).

In a subset analysis of the ongoing 60-patient United States trial of Revascor™ for congestive heart failure, 22 patients were found to have reduced myocardial blood flow at baseline by SPECT perfusion scan, indicating the presence of ischemic heart muscle. Of these, 17 were randomized to receive treatment with Revascor™ while 5 were randomized as controls. Six months after treatment with a single injection of Revascor™ there was significant improvement in blood flow to the ischemic heart muscle, with 51% reduction in myocardial ischemia (p=0.01). In contrast, no change in blood flow to the ischemic heart muscle was seen at six months in the controls.

These improvements in blood flow and in myocardial ischemia in patients treated with Revascor™ were accompanied by a 75% reduction in the risk of Major Adverse Cardiac Events (MACE) over a mean follow-up period of 21 months compared with controls with myocardial ischemia and no change in blood flow. MACE are defined as a clinical composite of death due to cardiac causes, non-fatal heart attacks, or revascularization episodes. "These positive results open up major new market opportunities for our lead cardiovascular product Revascor™," Professor Itescu told the global investor forum.

"By improving blood flow to ischemic heart muscle Revascor™ may be an effective treatment for a broader range of vascular heart conditions and their life-threatening consequences.

“We are particularly excited about the prospect that Revascor™ could be highly effective for patients with chronic refractory angina who do not have other therapeutic options and are so debilitated by pain that their physical activity is either markedly restricted or non-existent.
“Indeed, in an earlier pilot trial in Australia where we treated such patients with a single injection of an autologous, or patient specific, version of Revascor™ our proprietary stem cells were highly effective for reduction in angina symptoms and use of anti-angina medications for as long as six months."...

We managed to kick off the 220 Heart Attack Trials ,but (IMO only) thanks to the previous TEVA leadership (..blah blah) the very promising chronic refractory angina P2 trials are yet to be commenced.

The Regen space is mind blowing for many and they have good reason to be so. What's just as exciting is know we are invested in the industries pacesetter.

Hoping to get an update on Japan soon..cant be too far away in my opinion.

GLTAH